Author, year | Journal | Follow-up (months) | Treatment | Patients (n) | Mean age | Women (%) | Symptoms duration (months) |
---|---|---|---|---|---|---|---|
Allan et al. [15] | Spine | 13.0 | Fentanyl | 338 | 53.4 | 61.0 | 122.5 |
Morphine | 342 | 54.7 | 38.0 | 127.0 | |||
Atkinson et al. [16] | Pain | 2.0 | Maprotiline | 33 | 49.2 | 36.9 | 174.0 |
Paroxetine | 34 | Â | Â | Â | |||
Placebo | 36 | Â | Â | Â | |||
Atkinson et al. [17] | Pain | 3.0 | Gabapentin | 55 | 57.8 | 18.9 | 206.0 |
Placebo | 53 | 54.6 | 24.5 | 213.5 | |||
Baron et al. [18] | Pain Practice | 2.8 | Tapentadol | 154 | 58.5 | 61.5 | 112.8 |
Tapentadol & Pregabalin | 159 | 56.3 | 54.1 | 104.4 | |||
Bedaiwi et al. [4] | Arthritis Care & Research | 1.0 | Acetaminophen | 25 | 37.2 | 44.0 | Â |
Celecoxib | 25 | 43.4 | 52.0 | Â | |||
Birbara et al. [19] | J Pain | 3.0 | Etoricoxib | 101 | 52.3 | 63.4 | 145.2 |
Etoricoxib | 106 | 52.2 | 63.2 | 129.6 | |||
Placebo | 107 | 51.0 | 55.1 | 128.4 | |||
Bråten et al. [20] | BMJ | 12.0 | Amoxicillin | 89 | 44.7 | 60.0 | 36.0 |
Placebo | 91 | 45.2 | 57.0 | 40.8 | |||
Buynak et al. [21] | Expert Opin. Pharmacother | Â | Oxycodone | 328 | 50.0 | 55.2 | Â |
Tapentadol | 318 | 49.4 | 61.0 | Â | |||
Placebo | 319 | 50.4 | 57.7 | Â | |||
Chu et al. [22] | Pain | 1.0 | Morphine | 69 | 44.0 | 36.2 | Â |
Placebo | 70 | 46.0 | 51.4 | Â | |||
Coats et al. [23] | Clinical Therapeutics | 1.0 | Valdecoxib | 148 | 48.6 | 54.7 | 139.2 |
Placebo | 145 | 48.7 | 58.6 | 130.8 | |||
Gordon et al. [24] | Clin Ther | 2.0 | Buprenorphine | 39 | 50.7 | 60.3 | 154.8 |
Placebo | 39 | Â | Â | Â | |||
Hale et al. [25] | J Pain | 3.0 | Oxymorphone Release | 70 | 48.2 | 57.1 | Â |
Placebo | 72 | 46.0 | 33.3 | Â | |||
Hwang et al. [26] | Pain Res and Man | 1.9 | Fentanyl | 52 | 59.0 | 57.7 | Â |
Gabapentin | 56 | 58.2 | 53.6 | Â | |||
Jamison et al. [27] | SPINE | 4.0 | Naproxen | 12 | 42.6 | 57.1 | 79.1 |
Oxycodone | 13 | Â | Â | Â | |||
Oxycodone & Morphine | 11 | Â | Â | Â | |||
Kalita et al. [28] | J Neurological Sci | 3.5 | Amitriptyline | 103 | 41.6 | 45.5 | 35.2 |
Pregabalin | 97 | 42.0 | Â | 35.9 | |||
Katz et al. [29] | Am J Pain | 4.0 | Bupropion | 21 | 49.8 | 57.1 | Â |
Placebo | 23 | 51.4 | 39.1 | Â | |||
Katz et al. [30] | Curr Med Res Opin | 3.0 | Oxymorphone | 105 | 51.3 | 56.2 | Â |
Placebo | 100 | 48.1 | 50.0 | Â | |||
Khoromi et al. [31] | J Pain | 4.5 | Topiramate & Placebo | 21 | Â | Â | Â |
Placebo & Topiramate | 20 | Â | Â | Â | |||
Klinger et al. [32] | PAIN | Â | Opioid | 12 | 50.0 | 18.75 | 119.33 |
Opioid & Conditioning | 12 | 53.0 | 18.75 | 158.83 | |||
Placebo | 12 | 50.8 | 18.75 | 165.67 | |||
Placebo & Conditioning | 12 | 50.3 | 18.75 | 162.17 | |||
Konno et al. [33] | SPINE | 3.5 | Placebo | 226 | 57.8 | 54.0 | 123.6 |
Duloxetine | 230 | 60 | 50.0 | 117.6 | |||
Krebs et al. [34] | JAMA | 12.0 | Opioid | 120 | 56.8 | 13.0 | Â |
Non-Opioid group | 120 | 59.7 | 13.0 | Â | |||
Markman et al. [35] | Neurology | 1.0 | Pregabalin & diphenhydramine | 14 | 71.1 | 29.0 | Â |
Diphenhydramine & pregabalin | 15 | 69.0 | 33.0 | Â | |||
Muehlbacher et al. [36] | Clin J Pain | 2.5 | Topiramate | 48 | 48.8 | 39.6 | Â |
Placebo | 48 | 48.7 | 35.4 | Â | |||
Perrot et al. [37] | Clin Ther | 0.3 | Paracetamol & Tramadol | 59 | 56.5 | 64.4 | Â |
Tramadol | 60 | 54.1 | 51.7 | Â | |||
Pheasant et al. [38] | SPINE | Â | Atropine | 6 | 47.2 | 75.0 | 118.8 |
Amitriptyline | 10 | Â | Â | Â | |||
Pota et al. [39] | Pain Manage | 1.5 | Buprenorphine & pregabalin | 22 | 55.0 | 50.0 | 15.0 |
Buprenorphine | 22 | Â | Â | Â | |||
Robertson et al. [40] | JAMA Neur | 2.0 | Pregabalin | 10 | 57.0 | 39.0 | Â |
Gabapentin | 8 | Â | Â | Â | |||
Romano et al. [41] | J Orthop Traumatol | 3.0 | Several protocols combining Pregabalin, Celecoxib and Placebo | 36 | 53.0 | 55.6 | Â |
Ruoff et al. [42] | Clinical Therapeutics | 3.0 | Tramadol & Acetaminophen | 161 | 53.6 | 67.1 | Â |
Placebo | 157 | 54.1 | 59.2 | Â | |||
Sakai et al. [43] | Eur Spine J | Â | Pregabalin | 30 | 72.0 | 30.0 | Â |
Tramadol & Acetaminophen | 30 | 72.6 | 36.7 | Â | |||
Schiphorst Preuper et al. [44] | Eur Spine J | 0.5 | Tramadol & Acetaminophen | 25 | 42.0 | 72.0 | 18.0 |
Placebo | 25 | 44.0 | 64.0 | 24.0 | |||
Schliessbach et al. [45] | European J Pain | Â | Clobazam | 49 | 54.3 | 59.0 | 145.2 |
Placebo | Â | Â | Â | Â | |||
Schliessbach et al. [46] | PLoS ONE | Â | Imipramine | 50 | 54.4 | 64.0 | 134.4 |
Placebo | Â | Â | Â | Â | |||
Schliessbach et al. [47] | European J Pain | Â | Oxycodone | 50.0 | Â | Â | Â |
Imipramine | 50.0 | Â | Â | Â | |||
Clobazam | 49.0 | Â | Â | Â | |||
Schukro et al. [48] | Anesthesiology | 1.0 | Duloxetine | 25 | 57.9 | 51.0 | 18.0 |
Placebo | Â | Â | Â | Â | |||
Shell et al. [49] | Am J Ther | 1.0 | Naproxen | 43 | Â | Â | Â |
Theramine | 42 | Â | Â | Â | |||
Naproxene & Theramine | 44 | Â | Â | Â | |||
Skljarevski et al. [50] | J Pain | 3.0 | Placebo | 203 | 53.4 | 63.1 | 104.4 |
Duloxetine | 198 | 54.9 | 59.6 | 99.6 | |||
Skljarevski et al. [51] | Pain Medicine | 9.0 | Duloxetine | 83 | 51.2 | 65.1 | 104.4 |
Duloxetine & Placebo | 98 | 52.2 | 63.3 | 120.0 | |||
Steiner et al. [52] | J Pain Symptom Management | 3.0 | Buprenorphine | 257 | 48.8 | 52.0 | Â |
Placebo | 284 | 50.0 | 58.0 | Â | |||
Takahashi et al. [53] | Fukushima J Med Sci | 3.0 | NSAID | 15 | 53.3 | 53.3 | 5.92 |
Control group | 18 | 57.6 | 55.6 | 7.63 | |||
Tetsunaga et al. [54] | J Orthop Sci | 2.0 | Tramadol | 35 | 65.4 | 62.9 | 46.0 |
NSAID | 35 | 62.3 | 62.9 | 54.2 | |||
Ãœberall et al. [55] | Curr Med Res Opin | 1.0 | Placebo | 120 | 59.2 | 55.8 | 76.4 |
Flupirtine | 119 | 58.6 | 68.9 | 69.2 | |||
Tramadol | 116 | 57.6 | 61.2 | 71.7 | |||
Urquhart et al. [56] | JAMA Intern Med | 6.0 | Amitriptyline | 72 | 53.5 | 39.0 | 159.6 |
Control group | 74 | 56.0 | 38.0 | 182.4 | |||
Webster et al. [57] | J Pain | 3.0 | Placebo | 101 | 48.7 | 61.4 | Â |
Oxycodone | 206 | 47.9 | 61.2 | Â | |||
Oxytrex | 206 | 47.8 | 61.7 | Â | |||
Oxytrex | 206 | 47.9 | 61.7 | Â | |||
Yang et al. [58] | Yonsei Med J | 0.5 | Aceclofenac | 50 | 57.6 | 76.0 | 50.0 |
Aceclofenac | 50 | 56.9 | 76.0 | 91.6 | |||
Zaringhalam et al. [59] | Chinese Med | 2.5 | Baclofen | 21 | 55.1 | Â | 80.4 |
Acupuncture | 21 | 54.2 | Â | 85.2 | |||
Baclofen & Acupuncture | 21 | 54.2 | Â | 82.8 | |||
Control group | 21 | 54.3 | Â | 84.0 | |||
Zerbini et al. [60] | Curr Med Res Opin | 1.0 | Etoricoxib | 224 | 51.7 | 71.9 | 99.6 |
Diclofenac | 222 | 52.2 | 71.6 | 99.6 |